How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

Company Summary - BioCryst (BCRX) is currently an intriguing investment choice due to solid earnings estimate revision activity and a favorable Zacks Rank [1][3] - Over the past month, current quarter estimates improved from a loss of $0.09 per share to a loss of$0.07 per share, while current year estimates increased from a loss of $0.07 per share to a loss of$0.06 per share [4] Industry Summary - The Medical – Drugs industry has a Zacks Industry Rank of 75 out of more than 250 industries, indicating strong positioning compared to other segments [2] - The positive trends in the Medical – Drugs space suggest that a rising tide may benefit multiple securities within the industry [2][5]